There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech Inc (KRYS) and Applied Therapeutics Inc (APLT) with bullish sentiments.
Krystal Biotech Inc (KRYS)
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech Inc. The company’s shares opened today at $37.83, close to its 52-week high of $39.95.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 15.8% and a 59.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.
Krystal Biotech Inc has an analyst consensus of Strong Buy, with a price target consensus of $44.38, representing a 17.3% upside. In a report issued on June 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $38 price target.
See today’s analyst top recommended stocks >>
Applied Therapeutics Inc (APLT)
Cowen & Co. analyst Marc Frahm maintained a Buy rating on Applied Therapeutics Inc today. The company’s shares opened today at $8.34, close to its 52-week low of $7.95.
According to TipRanks.com, Frahm is a 4-star analyst with an average return of 8.5% and a 64.3% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and X4 Pharmaceuticals Inc.
Applied Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $24.33, implying a 191.7% upside from current levels. In a report issued on June 10, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $24 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
